Literature DB >> 7743304

Are serum concentrations of nitric oxide metabolites useful for predicting the clinical outcome of severe ulcerative colitis?

D C Rees1, J Satsangi, P L Cornelissen, S P Travis, J White, D P Jewell.   

Abstract

OBJECTIVE: To determine serum concentrations of nitric oxide metabolites (NOX) in patients with severe ulcerative colitis and to assess whether these concentrations predict clinical outcome. PATIENTS: Twenty-six patients (16 men and 10 women, mean age 46 years) with severe ulcerative colitis requiring hospitalization for parenteral steroid therapy. Thirteen patients had a complete clinical response and symptoms resolved after 5 days of parenteral steroid administration; 13 made an incomplete recovery and needed further treatment (six cyclosporin, seven colectomy).
METHODS: Serum concentrations of NOX and C-reactive protein (CRP) were measured daily for 3 days in all patients and as clinically indicated thereafter. The normal range for NOX was established by measuring the concentration in 25 healthy controls.
RESULTS: Mean serum NOX and CRP concentrations were significantly elevated in both the patients with a complete and those with an incomplete response compared with controls (P < 0.001) on day 1 and fell during the first 3 days of therapy. On day 3, mean serum concentrations of NOX and CRP were lower in the patients with a complete response, but only the difference in CRP attained statistical significance (P = 0.02). There was no correlation between NOX and CRP concentrations.
CONCLUSIONS: In the majority of patients with severe ulcerative colitis, circulating concentrations of NOX are increased at presentation and fall promptly during parenteral steroid therapy, irrespective of clinical outcome. However, in a small number of patients NOX concentrations do not fall during steroid treatment and such patients will probably require additional medical therapy or surgery.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7743304

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  7 in total

1.  Mesenteric blood flow is related to disease activity and risk of relapse in ulcerative colitis: a prospective follow up study.

Authors:  D Ludwig; S Wiener; A Brüning; K Schwarting; G Jantschek; K Fellermann; M Stahl; E F Stange
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

2.  Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis.

Authors:  R K Linskens; A A van Bodegraven; M Schoorl; H A Tuynman; P Bartels
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

3.  Nitric oxide effect on colonocyte metabolism: co-action of sulfides and peroxide.

Authors:  W E Roediger; W J Babidge
Journal:  Mol Cell Biochem       Date:  2000-03       Impact factor: 3.396

4.  Predicting outcome in severe ulcerative colitis.

Authors:  S P Travis; J M Farrant; C Ricketts; D J Nolan; N M Mortensen; M G Kettlewell; D P Jewell
Journal:  Gut       Date:  1996-06       Impact factor: 23.059

5.  Assessment of fractionated exhaled nitric oxide as a biomarker for the treatment of eosinophilic esophagitis.

Authors:  John Leung; Ann Nguyen-Traxler; Erika M Lee; Jason S Yip; Joel V Weinstock; Walter W Chan; Peter Ngo; Barbara J Weinstein; Peter A Bonis
Journal:  Allergy Asthma Proc       Date:  2012 Nov-Dec       Impact factor: 2.587

6.  Poor Relationship Between Fractionated Exhaled Nitric Oxide and Disease Activity in Eosinophilic Esophagitis.

Authors:  Kimberly Johnson; Vivek Iyer; David Katzka; Karthik Ravi; Ryan Lennon; Richard Pendegraft; Debra Geno; Jeffrey Alexander
Journal:  Dysphagia       Date:  2018-07-24       Impact factor: 3.438

7.  Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases.

Authors:  Golshid Jahanshahi; Vian Motavasel; Ali Rezaie; Ali A Hashtroudi; Naser E Daryani; Mohammad Abdollahi
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.487

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.